Scott J Rodig

List of Publications by Year in Descending Order

219 papers	18,620 citations	59 h-index	136 g-index
241 ext. papers	23,901 ext. citations	8.3 avg, IF	6.18 L-index

#	Paper	IF	Citations
219	Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.. *Lancet Oncology, The*, **2022**,	21.7	9
218	A phase II trial of abemaciclib (abema) and atezolizumab (atezo) in unselected and CDK12-loss metastatic castration-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2022**, 40, TPS213-TPS213	2.2	9
217	Abstract P1-04-05: Multiplexed immunofluorescence staining of intra-tumoral immune cell populations and associations with immunohistochemical, clinical, and pathologic variables in breast cancer. *Cancer Research*, **2022**, 82, P1-04-05-P1-04-05	10.1	0
216	FOXP3+ T-cell infiltration is associated with improved outcomes in metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICI).. *Journal of Clinical Oncology*, **2022**, 40, 549-549	2.2	
215	MITI minimum information guidelines for highly multiplexed tissue images.. *Nature Methods*, **2022**, 19, 262-267	21.6	2
214	Landscape of helper and regulatory antitumour CD4 T cells in melanoma.. *Nature*, **2022**, 605, 532-538	50.4	2
213	655 Landscape of helper and regulatory CD4+ T cells in melanoma **2021**, 9, A684-A684		1
212	67 Cancer aneuploidy is associated with a distinct tumor immune microenvironment and impacts outcomes to immune checkpoint inhibition in nonsquamous non-small cell lung cancer **2021**, 9, A74-A75		
211	Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer **2021**, 9,		5
210	700 Increasing MHC-I expression to potentiate immune checkpoint blockade therapy **2021**, 9, A728-A728		
209	374 A phase IB trial of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors **2021**, 9, A402-A404		1
208	Genetic Perturbation of CD70/CD27 Co-Stimulation Promotes the Development of Bcl6-Driven Diffuse Large B-Cell Lymphoma. *Blood*, **2021**, 138, 713-713	2.2	
207	Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia. *Cancer Research Communications*, **2021**, 1, 30-40		2
206	Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. *Cancer Discovery*, **2021**, 11, 1952-1969	24.4	12
205	Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. *Haematologica*, **2021**,	6.6	9
204	First-in-human CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) in patients with recurrent high-grade glioma.. *Journal of Clinical Oncology*, **2021**, 39, 2009-2009	2.2	1
203	Is radiation necrosis in radiated melanoma brain metastasis increasing because immunotherapy is contributing to this or are patients just living longer?. *Journal of Clinical Oncology*, **2021**, 39, e21518-e21518	2.2	

202	CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. *Blood*, **2021**, 138, 1081-1085	2.2	14
201	Clinicopathologic and genomic correlates of tumor-infiltrating immune cells and immunotherapy efficacy in NSCLC.. *Journal of Clinical Oncology*, **2021**, 39, 9121-9121	2.2	1
200	Clinicopathologic, genomic, and tumor microenvironment correlates of aneuploidy and immunotherapy outcomes in NSCLC.. *Journal of Clinical Oncology*, **2021**, 39, 9119-9119	2.2	
199	Association of a very high tumor mutational load with increased CD8+ and PD-1+ T-cell infiltration and improved clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels in non-small cell lung cancer.. *Journal of Clinical Oncology*, **2021**, 39, 9018-9018	2.2	1
198	Pathology of durable stable disease in melanoma patients treated with ipilimumab, nivolumab, or ipilimumab, and nivolumab combination therapy.. *Journal of Clinical Oncology*, **2021**, 39, 9567-9567	2.2	0
197	Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients. *Npj Precision Oncology*, **2021**, 5, 62	9.8	6
196	Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. *Nature Cancer*, **2021**, 2, 66-82	15.4	35
195	Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. *Blood*, **2021**, 137, 1353-1364	2.2	11
194	Expansion sequencing: Spatially precise in situ transcriptomics in intact biological systems. *Science*, **2021**, 371,	33.3	64
193	Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. *Nature Medicine*, **2021**, 27, 515-525	50.5	69
192	Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. *Cancer Discovery*, **2021**, 11, 1524-1541	24.4	13
191	SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. *Journal of Thoracic Oncology*, **2021**, 16, 1176-1187	8.9	6
190	Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network. *Clinical Cancer Research*, **2021**, 27, 5072-5083	12.9	3
189	Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss. *Oncogene*, **2021**, 40, 5718-5729	9.2	0
188	Inactivation of Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade. *Cancer Discovery*, **2020**, 10, 1296-1311	24.4	16
187	P2RY8-CRLF2Fusion-Positive Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Response to Novel Therapy. *JCO Precision Oncology*, **2020**, 4, 152-160	3.6	1
186	Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. *Nature Communications*, **2020**, 11, 1459	17.4	82
185	Multiparametric in situ imaging of NPM1-mutated acute myeloid leukemia reveals prognostically-relevant features of the marrow microenvironment. *Modern Pathology*, **2020**, 33, 1380-1388	9.8	4

184	CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas. *Haematologica*, **2020**, 105, 1361-1368	6.6	15
183	Title: Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202). *Blood*, **2020**, 136, 25-26	2.2	2
182	CIMAC-CIDC tissue imaging harmonization.. *Journal of Clinical Oncology*, **2020**, 38, 3125-3125	2.2	1
181	Overview of Tissue Imaging Methods. *Methods in Molecular Biology*, **2020**, 2055, 455-465	1.4	11
180	Meta-Analysis of PD-L1 Expression As a Predictor of Survival After Checkpoint Blockade.. *JCO Precision Oncology*, **2020**, 4, 1196-1206	3.6	4
179	Nodular primary cutaneous melanoma is associated with PD-L1 expression. *European Journal of Dermatology*, **2020**, 30, 352-357	0.8	1
178	Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. *Clinical Cancer Research*, **2020**, 26, 5140-5152	12.9	71
177	Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. *Journal of Clinical Oncology*, **2020**, 38, 3095-3106	2.2	78
176	A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. *Nature Medicine*, **2020**, 26, 1468-1479	50.5	39
175	Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. *JAMA Oncology*, **2020**, 6, 1563-1570	13.4	77
174	PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. *Blood Advances*, **2020**, 4, 122-126	7.8	24
173	Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair-Deficient Colorectal Cancer. *Cancer Immunology Research*, **2019**, 7, 1230-1236	12.5	38
172	Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. *Cancer Cell*, **2019**, 35, 885-900.e10	24.3	213
171	Disruption of results in myeloproliferative neoplasms in zebrafish. *DMM Disease Models and Mechanisms*, **2019**, 12,	4.1	9
170	The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy. *Clinical Cancer Research*, **2019**, 25, 4644-4655	12.9	41
169	PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. *Blood*, **2019**, 134, 22-29	2.2	78
168	Targetable genetic alterations of () drive immunoglobulin expression in diffuse large B cell lymphoma. *Science Translational Medicine*, **2019**, 11,	17.5	28
167	CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel. *Blood*, **2019**, 134, 203-203	2.2	30

166	Analysis of colorectal cancer patients treated on ETCTN 10021: A multicenter randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation.. *Journal of Clinical Oncology*, **2019**, 37, 49-49	2.2	4
165	T Cell Determinants of Response and Resistance to PD-1 Blockade in Richter's Transformation. *Blood*, **2019**, 134, 680-680	2.2	0
164	Comparative Genomic Analyses Defines Shared and Unique Features of cHL and PMBL and New Mechanisms of Sensitivity to PD-1 Blockade. *Blood*, **2019**, 134, 1493-1493	2.2	
163	Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Naïve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study. *Blood*, **2019**, 134, 2015-2015	2.2	0
162	Subsets of exhausted CD8 T cells differentially mediate tumor control and respond to checkpoint blockade. *Nature Immunology*, **2019**, 20, 326-336	19.1	522
161	The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative. *Blood*, **2019**, 134, 2059-2069	2.2	30
160	Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade. *Blood*, **2019**, 134, 2369-2382	2.2	32
159	Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. *Blood Advances*, **2019**, 3, 4065-4080	7.8	38
158	Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer. *Oncologist*, **2019**, 24, 1013-1021	5.7	10
157	Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. *Nature*, **2019**, 565, 234-239	50.4	569
156	Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. *Science Advances*, **2018**, 4, eaar2766	14.3	254
155	A Simple and Effective Method for Flow Cytometric Study of Lymphoid Malignancies Using Needle Core Biopsy Specimens. *Cytometry Part B - Clinical Cytometry*, **2018**, 94, 637-643	3.4	3
154	Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. *Nature Medicine*, **2018**, 24, 679-690	50.5	659
153	Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. *Nature Medicine*, **2018**, 24, 1143-1150	50.5	131
152	MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. *Science Translational Medicine*, **2018**, 10,	17.5	227
151	Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma. *OncoImmunology*, **2018**, 7, e1440930	7.2	22
150	Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. *Blood*, **2018**, 132, 1495-1506	2.2	69
149	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. *Nature Genetics*, **2018**, 50, 1271-1281	36.3	249

148	Mass cytometry of Hodgkin lymphoma reveals a CD4 regulatory T-cell-rich and exhausted T-effector microenvironment. *Blood*, **2018**, 132, 825-836	2.2	85
147	PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation. *Blood*, **2018**, 132, 1650-1650	2.2	2
146	PD-1 Blockade for Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation. *Blood*, **2018**, 132, 706-706	2.2	3
145	Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202). *Blood*, **2018**, 132, 2908-2908	2.2	5
144	Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity. *Blood*, **2018**, 132, 92-92	2.2	55
143	Comprehensive Genomic Analysis of Primary Mediastinal B-Cell Lymphoma. *Blood*, **2018**, 132, 1564-1564	2.2	4
142	Comprehensive Genomic Analysis of Flow-Sorted Hodgkin Reed Sternberg Cells Reveals Additional Genetic Bases of Immune Evasion. *Blood*, **2018**, 132, 1559-1559	2.2	2
141	Integrated Genetic and Topological Analysis Reveals a Hodgkin-like Mechanism of Immune Escape in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma. *Blood*, **2018**, 132, 1579-1579	2.2	2
140	Effect of dexamethasone in glioblastoma (GBM) patients on systemic and intratumoral T-cell responses induced by personalized neoantigen-targeting vaccine.. *Journal of Clinical Oncology*, **2018**, 36, 2020-2020	2.2	5
139	The tumor-immune microenvironment (TME) in HR+/HER2- metastatic breast cancer (mBC): Relationship to non-metastatic (met) tumors and prior treatment (tx) received.. *Journal of Clinical Oncology*, **2018**, 36, 1054-1054	2.2	
138	Implications of the tumor immune microenvironment for staging and therapeutics. *Modern Pathology*, **2018**, 31, 214-234	9.8	182
137	Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 514-520	4.7	27
136	Reply to Z. Wu et al. *Journal of Clinical Oncology*, **2018**, 36, 2657	2.2	
135	Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. *Journal of Clinical Oncology*, **2018**, 36, 942-950	2.2	175
134	ATIM-32. PERSONALIZED NEOANTIGEN-TARGETING VACCINE GENERATES ROBUST SYSTEMIC AND INTRATUMORAL T CELL RESPONSES IN GLIOBLASTOMA (GBM) PATIENTS. *Neuro-Oncology*, **2018**, 20, vi8-vi8	1	78
133	Characterization of the Neuroendocrine Tumor Immune Microenvironment. *Pancreas*, **2018**, 47, 1123-1129	2.6	42
132	Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. *International Journal of Radiation Oncology Biology Physics*, **2018**, 102, 137-145	4	15
131	Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression. *OncoImmunology*, **2017**, 6, e1277308	7.2	60

130	Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. *Immunity*, **2017**, 46, 197-204	32.3	288
129	Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. *Cancer*, **2017**, 123, 3285-3290	6.4	106
128	Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity. *Laboratory Investigation*, **2017**, 97, 207-216	5.9	13
127	Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer. *Cancer Immunology Research*, **2017**, 5, 1046-1055	12.5	25
126	Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status. *Journal of Clinical Oncology*, **2017**, 35, 1836-1844	2.2	89
125	Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. *Blood*, **2017**, 130, 2420-2430	2.2	174
124	An immunogenic personal neoantigen vaccine for patients with melanoma. *Nature*, **2017**, 547, 217-221	50.4	1375
123	Differential contribution of the mitochondrial translation pathway to the survival of diffuse large B-cell lymphoma subsets. *Cell Death and Differentiation*, **2017**, 24, 251-262	12.7	34
122	Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. *Blood Advances*, **2017**, 1, 2643-2654	7.8	77
121	Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma (HNSCC).. *Journal of Clinical Oncology*, **2017**, 35, 6012-6012	2.2	52
120	Immune biomarkers and treatment (tx) outcome in hormone receptor-positive (HR+) breast cancer (BC) patients (pts) treated with preoperative chemotherapy (preop chemo) plus bevacizumab (bev).. *Journal of Clinical Oncology*, **2017**, 35, e12134-e12134	2.2	
119	Association of distinct baseline tissue biomarkers with response to nivolumab (NIVO) and ipilimumab (IPI) in melanoma: CheckMate 064.. *Journal of Clinical Oncology*, **2017**, 35, 9515-9515	2.2	
118	Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities. *Blood Advances*, **2016**, 1, 84-92	7.8	6
117	VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma. *Cancer Immunology Research*, **2016**, 4, 858-868	12.5	52
116	Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. *Blood*, **2016**, 127, 2203-13	2.2	51
115	Nivolumab for classical Hodgkin lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. *Lancet Oncology, The*, **2016**, 17, 1283-94	21.7	643
114	Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. *Cancer Immunology Research*, **2016**, 4, 1038-1048	12.5	54
113	A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma. *Cancer Medicine*, **2016**, 5, 3041-3050	4.8	30

112	Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. *Cancer Immunology Research*, **2016**, 4, 910-916	12.5	118
111	Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. *Journal of Clinical Oncology*, **2016**, 34, 2698-704	2.2	677
110	Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. *Cancer Immunology Research*, **2016**, 4, 679-87	12.5	54
109	Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. *Nature Communications*, **2016**, 7, 10501	17.4	846
108	MYC Immunohistochemistry to Identify MYC-Driven B-Cell Lymphomas in Clinical Practice. *American Journal of Clinical Pathology*, **2016**, 145, 166-79	1.9	22
107	Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. *JAMA Oncology*, **2016**, 2, 518-22	13.4	95
106	Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. *Cancer Immunology Research*, **2016**, 4, 124-35	12.5	236
105	Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma. *Blood*, **2016**, 128, 1110-1110	2.2	33
104	Distinct Patterns of PD-L1 and PD-L2 Expression By Tumor and Non-Tumor Cells in Patients with MM, MDS and AML. *Blood*, **2016**, 128, 1340-1340	2.2	9
103	DNA Copy Number Gains of TCF4 (E2-2) Are Associated with Poor Outcome in Diffuse Large B-Cell Lymphoma. *Blood*, **2016**, 128, 2686-2686	2.2	1
102	Chromosome 9p24.1/PD-L1/PD-L2Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade). *Blood*, **2016**, 128, 2923-2923	2.2	4
101	In Silico and Functional Characterization of TBL1XR1 as a Tumor Suppressor in Large B-Cell Lymphomas. *Blood*, **2016**, 128, 612-612	2.2	3
100	Double-Hit and Double-Expressor Lymphomas Are Not Associated with an Adverse Outcome after Allogeneic Stem Cell Transplantation. *Blood*, **2016**, 128, 830-830	2.2	3
99	Phase 2 study of nivolumab in metastatic leiomyosarcoma of the uterus.. *Journal of Clinical Oncology*, **2016**, 34, 11007-11007	2.2	11
98	Response and oligoclonal resistance to pembrolizumab in uterine leiomyosarcoma: Genomic, neoantigen, and immunohistochemical evaluation.. *Journal of Clinical Oncology*, **2016**, 34, 11043-11043	2.2	2
97	Phase I study of sapacitabine and seliciclib in patients with advanced solid tumors.. *Journal of Clinical Oncology*, **2016**, 34, 2503-2503	2.2	5
96	Immunogenicity of clear cell ovarian cancer: Association with ARID1A loss, microsatellite instability and endometriosis.. *Journal of Clinical Oncology*, **2016**, 34, 5514-5514	2.2	8
95	Analysis of immune infiltrates in a genomically characterized clinical cohort of head and neck squamous cell carcinoma (HNSCC) patients (pts).. *Journal of Clinical Oncology*, **2016**, 34, 6052-6052	2.2	1

94	Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)A phase 2 study.. *Journal of Clinical Oncology*, **2016**, 34, 7535-7535	2.2	7
93	Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. *Oncotarget*, **2016**, 7, 13587-98	3.3	361
92	Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers. *Oncotarget*, **2016**, 7, 32925-32	3.3	191
91	HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma. *Blood*, **2016**, 128, 2517-2526	2.2	30
90	Prevalence and predictors of androgen receptor and programmed death-ligand 1 in -associated and sporadic triple-negative breast cancer. *Npj Breast Cancer*, **2016**, 2, 16002	7.8	22
89	The Role of Surgical Pathology in Guiding Cancer Immunotherapy. *Annual Review of Pathology: Mechanisms of Disease*, **2016**, 11, 313-41	34	12
88	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. *Journal of Clinical Oncology*, **2016**, 34, 2690-7	2.2	472
87	Targetable genetic features of primary testicular and primary central nervous system lymphomas. *Blood*, **2016**, 127, 869-81	2.2	317
86	Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. *British Journal of Haematology*, **2016**, 175, 841-850	4.5	38
85	Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. *JAMA Oncology*, **2015**, 1, 1319-23	13.4	378
84	Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. *Cancer Cell*, **2015**, 28, 29-41	24.3	75
83	Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma. *Cancer Immunology Research*, **2015**, 3, 1123-1129	12.5	98
82	Immunological mechanisms of the antitumor effects of supplemental oxygenation. *Science Translational Medicine*, **2015**, 7, 277ra30	17.5	334
81	An oncogenic role for alternative NF-B signaling in DLBCL revealed upon deregulated BCL6 expression. *Cell Reports*, **2015**, 11, 715-26	10.6	57
80	Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma. *Clinical Cancer Research*, **2015**, 21, 2851-60	12.9	72
79	The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo. *Cell*, **2015**, 161, 319-32	56.2	233
78	Surface Light Chain Expression in Primary Mediastinal Large B-Cell Lymphomas by Multiparameter Flow Cytometry. *American Journal of Clinical Pathology*, **2015**, 144, 635-41	1.9	9
77	Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens. *Journal of Molecular Diagnostics*, **2015**, 17, 19-30	5.1	19

76	Mutations in G protein □subunits promote transformation and kinase inhibitor resistance. *Nature Medicine*, **2015**, 21, 71-5	50.5	60
75	A zebrafish model of myelodysplastic syndrome produced through tet2 genomic editing. *Molecular and Cellular Biology*, **2015**, 35, 789-804	4.8	45
74	PD-1 blockade with nivolumab in relapsed or refractory Hodgkin□s lymphoma. *New England Journal of Medicine*, **2015**, 372, 311-9	59.2	2513
73	Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. *Journal of Translational Medicine*, **2015**, 13, 294	8.5	32
72	Duration of symptoms does not correlate with results of T-cell gene rearrangement studies in patients evaluated for cutaneous T-cell lymphoma. *Journal of Cutaneous Pathology*, **2015**, 42, 618-21	1.7	0
71	RelA-Induced Interferon Response Negatively Regulates Proliferation. *PLoS ONE*, **2015**, 10, e0140243	3.7	13
70	Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. *Cancer Immunology Research*, **2015**, 3, 855-63	12.5	53
69	PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. *Cancer Immunology Research*, **2015**, 3, 1308-15	12.5	96
68	Quantitative Assessment of PD-L1 Expression in Classical Hodgkin Lymphoma Suggests a Critical Role for Tumor Associated Macrophages in Suppressing Anti-Tumor Immunity. *Blood*, **2015**, 126, 1440-1440	2.2	4
67	Sequencing-Based Detection of Circulating Tumor DNA in the Autologous Stem Cell Grafts of Patients with Diffuse Large B-Cell Lymphoma Undergoing Hematopoietic Stem Cell Transplantation. *Blood*, **2015**, 126, 3156-3156	2.2	2
66	Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation. *Blood*, **2015**, 126, 522-522	2.2	3
65	Prevalence and predictors of androgen receptor (AR) and programmed death-ligand 1 (PD-L1) expression in BRCA1-associated and sporadic triple negative breast cancer (TNBC).. *Journal of Clinical Oncology*, **2015**, 33, 1005-1005	2.2	2
64	Association of POLE-mutated and MSI endometrial cancers with an elevated number of tumor-infiltrating and peritumoral lymphocytes and higher expression of PD-L1.. *Journal of Clinical Oncology*, **2015**, 33, 5511-5511	2.2	2
63	Tumor infiltrating and peritumoral T cells and expression of PD-L1 in BRCA1/2-mutated high grade serous ovarian cancers.. *Journal of Clinical Oncology*, **2015**, 33, 5512-5512	2.2	5
62	Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia. *Oncotarget*, **2015**, 6, 25575-87	3.3	13
61	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. *Blood*, **2015**, 126, 176-176	2.2	1
60	Resolving the Biological Heterogeneity of B-Cell Lymphoma, Unclassifiable, with Features Intermediate Between DLBCL and BL (BCL-U) Using Quantitative Profiles of Oncogenic Signaling Networks. *Blood*, **2015**, 126, 3903-3903	2.2	
59	Comprehensive Analyses of Genetic Features Identify Coordinate Signatures in Diffuse Large B-Cell Lymphoma. *Blood*, **2015**, 126, 3922-3922	2.2	

58	Phenotypic and Transcriptional Characterization of Non-Hodgkin Lymphomas from Malawi Defines Targetable Disease Subsets. *Blood*, **2015**, 126, 2655-2655	2.2	
57	Diffuse Large B-Cell Lymphoma Patient-Derived Xenograft Models Capture Molecular and Biologic Heterogeneity and Inform Therapy. *Blood*, **2015**, 126, 817-817	2.2	
56	High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms. *Modern Pathology*, **2014**, 27, 1447-54	9.8	20
55	Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo. *Clinical Cancer Research*, **2014**, 20, 2674-83	12.9	97
54	Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. *American Journal of Surgical Pathology*, **2014**, 38, 1715-23	6.7	117
53	Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma - Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study. *Blood*, **2014**, 124, 289-289	2.2	7
52	Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies. *Blood*, **2014**, 124, 291-291	2.2	79
51	GNB1 Activating Mutations Promote Myeloid and Lymphoid Neoplasms Targetable By Combined PI3K/mTOR Inhibition. *Blood*, **2014**, 124, 3567-3567	2.2	3
50	Actionable Genetic Features of Primary Testicular and Primary Central Nervous System Lymphomas. *Blood*, **2014**, 124, 74-74	2.2	2
49	Immune checkpoint blockade for glioblastoma: Preclinical activity of single agent and combinatorial therapy.. *Journal of Clinical Oncology*, **2014**, 32, 2084-2084	2.2	3
48	Sequencing-Based Detection of Minimal Residual Disease Is Associated with Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Lymphoid Malignancies. *Blood* , **2014**, 124, 3961-3961	2.2	
47	Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. *Cancer Cell*, **2013**, 24, 777-90	24.3	491
46	Effect Of Treatment With The JAK2-Selective Inhibitor Fedratinib (SAR302503) On Bone Marrow Histology In Patients With Myeloproliferative Neoplasms With Myelofibrosis. *Blood*, **2013**, 122, 2823-2823	2.2	4
45	Disruption Of Super Enhancer-Driven Cancer Dependencies In Diffuse Large B-Cell Lymphoma. *Blood*, **2013**, 122, 3021-3021	2.2	1
44	Preclinical Analyses Of The Chemical JAK2 Inhibitor, SAR302503, In Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma. *Blood*, **2013**, 122, 4230-4230	2.2	1
43	CXCR4 Upregulation Is a Biomarker Of Sensitivity To Targeted Inhibition Of B-Cell Receptor Signaling In Diffuse Large B-Cell Lymphoma. *Blood*, **2013**, 122, 631-631	2.2	1
42	Targeting Oncogenic Interleukein-7 Receptor Signaling With N-Acetylcysteine In T-Cell Acute Lymphoblastic Leukemia. *Blood*, **2013**, 122, 2535-2535	2.2	
41	Alterations In Mitochondrial Priming May Be a Mechanism For Acquired Resistance To Therapy In Diffuse Large B-Cell Lymphoma. *Blood*, **2013**, 122, 1764-1764	2.2	

40	Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. *Cancer Cell*, **2012**, 22, 359-72	24.3	148
39	Phase I study of sequential sapacitabine and seliciclib in patients with advanced solid tumors.. *Journal of Clinical Oncology*, **2012**, 30, 3053-3053	2.2	
38	Impact of Operator Techniques On Quality of Bone Marrow Assessment. *Blood*, **2012**, 120, 2055-2055	2.2	
37	A Structural Basis for p53-Deficiency, Deregulated Cell Cycle and Unfavorable Outcome in Diffuse Large B-Cell Lymphoma. *Blood*, **2012**, 120, 1534-1534	2.2	
36	Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-Cell Lymphomas: A North American PTCL Study Group Project. *Blood*, **2012**, 120, 1545-1545	2.2	1
35	A Targeted Mutational Landscape of Angioimmunoblastic T-Cell Lymphoma: Association Between Advanced Age and Mutations in TET2 and DNMT3A. *Blood*, **2012**, 120, 299-299	2.2	
34	BET Bromodomain Inhibition Targets Both c-Myc and IL7R in Acute Lymphoblastic Leukemia. *Blood*, **2012**, 120, 672-672	2.2	
33	A Somatic Variant in MYD88 (L265P) Revealed by Whole Genome Sequencing Differentiates Lymphoplasmacytic Lymphoma From Marginal Zone Lymphomas. *Blood*, **2011**, 118, 261-261	2.2	5
32	Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma. *Blood*, **2011**, 118, 2912-2912	2.2	1
31	Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide,. *Blood*, **2011**, 118, 3966-3966	2.2	1
30	Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma. *Blood*, **2011**, 118, 2908-2908	2.2	1
29	Molecular Ontogeny of Donor-Derived Lymphomas Occurring After Transplantation,. *Blood*, **2011**, 118, 3671-3671	2.2	
28	Combined Targeting of the MET and FGF Receptor Tyrosine Kinases Induces Sustained AML Cell Death by Preventing Compensatory Upregulation of HGF in Response to MET Kinase Inhibition. *Blood*, **2011**, 118, 1405-1405	2.2	1
27	Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. *Blood*, **2010**, 116, 3268-77	2.2	903
26	The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas. *Haematologica*, **2010**, 95, 2056-62	6.6	20
25	Selective Inhibition of HDAC6 with a New Prototype Inhibitor (ACY-1215) Overcomes Bortezomib Resistance In Multiple Myeloma (MM). *Blood*, **2010**, 116, 2997-2997	2.2	1
24	Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib. *Blood*, **2010**, 116, 990-990	2.2	5
23	Mir-15a/16-1 Cluster Is Frequently Deleted In Primary Hodgkin Lymphoma and Modulates Multiple Survival Pathways Including AP-1. *Blood*, **2010**, 116, 746-746	2.2	

22	Integrative Analysis Reveals Multiple Alterations of p53 Signaling Pathway Components In Primary Diffuse Large B-Cell Lymphomas. *Blood*, **2010**, 116, 635-635	2.2	
21	Kruppel-Like Factor 10 (KLF10)-Deficient Mice Have Marked Defects In EPC Differentiation, Function, and Angiogenesis. *Blood*, **2010**, 116, 4314-4314	2.2	
20	Biology and Therapeutic Targeting of Sp1 Transactivation In Myeloma. *Blood*, **2010**, 116, 134-134	2.2	
19	Aberrant Expression of Hepatocyte Growth Factor Induces Autocrine MET Activation Providing a Novel Therapeutic Target In Acute Myeloid Leukemia.. *Blood*, **2010**, 116, 1042-1042	2.2	
18	Molecular Profiling of Extramedullary and Medullary Plasmacytomas Compared to Multiple Myeloma. *Blood*, **2010**, 116, 4042-4042	2.2	
17	Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. *Current Opinion in Investigational Drugs*, **2010**, 11, 1477-90		73
16	Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. *Clinical Cancer Research*, **2009**, 15, 5216-23	12.9	560
15	Expression and Targeted Inhibition of the Immunoregulatory Carbohydrate-Binding Lectin, Galectin 1, in EBV-Driven Post-Transplant Lymphoproliferative Disorders.. *Blood*, **2009**, 114, 96-96	2.2	
14	Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenstrom's Macroglobulinemia.. *Blood*, **2009**, 114, 4785-4785	2.2	
13	Significant Biological Role of Sp1 Transactivation in Myeloma: Potential Therapeutic Application.. *Blood*, **2009**, 114, 1841-1841	2.2	
12	AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features. *Clinical Cancer Research*, **2008**, 14, 3338-44	12.9	61
11	Characteristic expression patterns of TCL1, CD38, and CD44 identify aggressive lymphomas harboring a MYC translocation. *American Journal of Surgical Pathology*, **2008**, 32, 113-22	6.7	47
10	Aggressive Langerhans cell histiocytosis following T-ALL: clonally related neoplasms with persistent expression of constitutively active NOTCH1. *American Journal of Hematology*, **2008**, 83, 116-21	7.1	54
9	Combination of Nab-Rapamycin and Perifosine Induces Synergistic Cytotoxicity and Antitumor Activity Via Autophagy and Apoptosis in Multiple Myeloma (MM). *Blood*, **2008**, 112, 3663-3663	2.2	3
8	Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma. *American Journal of Surgical Pathology*, **2007**, 31, 106-12	6.7	68
7	Mantle cell lymphoma arising within primary nodal marginal zone lymphoma: a unique presentation of two uncommon B-cell lymphoproliferative disorders. *Cancer Genetics and Cytogenetics*, **2006**, 171, 44-51		16
6	Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). *Clinical Cancer Research*, **2006**, 12, 7174-9	12.9	118
5	The CD45 isoform B220 identifies select subsets of human B cells and B-cell lymphoproliferative disorders. *Human Pathology*, **2005**, 36, 51-7	3.7	22

4	BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders. *Human Pathology*, **2005**, 36, 1113-9	3.7	62
3	TRAF1 expression and c-Rel activation are useful adjuncts in distinguishing classical Hodgkin lymphoma from a subset of morphologically or immunophenotypically similar lymphomas. *American Journal of Surgical Pathology*, **2005**, 29, 196-203	6.7	42
2	IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology. *European Journal of Immunology*, **2000**, 30, 834-9	6.1	59
1	IL-12 gene-deficient C57BL / 6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology **2000**, 30, 834		4